BIOGEN INC. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
BIOGEN INC. (BIIB) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $21.82 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-04-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2013-04-25
- BIOGEN INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2013-03-31 was $21.82M, a 9.40% decline year-over-year.
- BIOGEN INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2012-12-31 was $9.21M, a 39.31% decline year-over-year.
- BIOGEN INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2012-09-30 was $15.20M, a 11.88% increase year-over-year.
- BIOGEN INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2012-06-30 was $19.00M, a 90.24% decline year-over-year.
- BIOGEN INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2012 was $67.49M, a 78.55% decline from fiscal 2011.
- BIOGEN INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2011 was $314.65M, a 71.48% increase from fiscal 2010.
- BIOGEN INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2010 was $183.49M, a 283.78% increase from fiscal 2009.
- BIOGEN INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2009 was $47.81M, a 73.21% decline from fiscal 2008.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2013-03-31 | $21.82M 10-Q · filed 2013-04-25 | $31.03M derived: sum of 2 quarters · filed 2013-04-25 | $46.23M derived: sum of 3 quarters · filed 2013-04-25 | $65.23M derived: sum of 4 quarters · filed 2013-04-25 |
| 2012-12-31 | $9.21M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $24.41M derived: sum of 2 quarters · filed 2013-02-05 | $43.41M derived: sum of 3 quarters · filed 2013-02-05 | $67.49M 10-K · filed 2013-02-05 |
| 2012-09-30 | $15.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-25 | $34.20M derived: sum of 2 quarters · filed 2012-10-25 | $58.28M 10-Q · filed 2012-10-25 | $73.46M derived: sum of 4 quarters · filed 2013-04-25 |
| 2012-06-30 | $19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-24 | $43.08M 10-Q · filed 2012-07-24 | $58.27M derived: sum of 3 quarters · filed 2013-04-25 | $71.85M derived: sum of 4 quarters · filed 2013-04-25 |
| 2012-03-31 | $24.08M 10-Q · filed 2013-04-25 | $39.26M derived: sum of 2 quarters · filed 2013-04-25 | $52.85M derived: sum of 3 quarters · filed 2013-04-25 | $247.57M derived: sum of 4 quarters · filed 2013-04-25 |
| 2011-12-31 | $15.18M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $28.77M derived: sum of 2 quarters · filed 2013-02-05 | $223.50M derived: sum of 3 quarters · filed 2013-02-05 | $314.65M 10-K · filed 2013-02-05 |
| 2011-09-30 | $13.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-25 | $208.31M derived: sum of 2 quarters · filed 2012-10-25 | $299.47M 10-Q · filed 2012-10-25 | $402.50M derived: sum of 4 quarters · filed 2013-02-05 |
| 2011-06-30 | $194.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-24 | $285.88M 10-Q · filed 2012-07-24 | $388.92M derived: sum of 3 quarters · filed 2013-02-05 | $406.18M derived: sum of 4 quarters · filed 2013-02-05 |
| 2011-03-31 | $91.16M 10-Q · filed 2012-05-01 | $194.19M derived: sum of 2 quarters · filed 2013-02-05 | $211.45M derived: sum of 3 quarters · filed 2013-02-05 | $221.82M derived: sum of 4 quarters · filed 2013-02-05 |
| 2010-12-31 | $103.04M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $120.29M derived: sum of 2 quarters · filed 2013-02-05 | $130.67M derived: sum of 3 quarters · filed 2013-02-05 | $183.49M 10-K · filed 2013-02-05 |
| 2010-09-30 | $17.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $27.63M derived: sum of 2 quarters · filed 2011-10-28 | $80.45M 10-Q · filed 2011-10-28 | $95.02M derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-06-30 | $10.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $63.19M 10-Q · filed 2011-07-26 | $77.77M derived: sum of 3 quarters · filed 2012-02-03 | $86.62M derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-03-31 | $52.82M 10-Q · filed 2011-04-21 | $67.39M derived: sum of 2 quarters · filed 2012-02-03 | $76.24M derived: sum of 3 quarters · filed 2012-02-03 | $83.58M derived: sum of 4 quarters · filed 2012-02-03 |
| 2009-12-31 | $14.57M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $23.42M derived: sum of 2 quarters · filed 2012-02-03 | $30.77M derived: sum of 3 quarters · filed 2012-02-03 | $47.81M 10-K · filed 2012-02-03 |
| 2009-09-30 | $8.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $16.19M derived: sum of 2 quarters · filed 2010-10-26 | $33.24M 10-Q · filed 2010-10-26 | $44.69M derived: sum of 4 quarters · filed 2011-02-04 |
| 2009-06-30 | $7.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20 | $24.39M 10-Q · filed 2010-07-20 | $35.84M derived: sum of 3 quarters · filed 2011-02-04 | $113.34M derived: sum of 4 quarters · filed 2011-02-04 |
| 2009-03-31 | $17.04M 10-Q · filed 2010-04-20 | $28.50M derived: sum of 2 quarters · filed 2011-02-04 | $106.00M derived: sum of 3 quarters · filed 2011-02-04 | |
| 2008-12-31 | $11.45M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $88.95M derived: sum of 2 quarters · filed 2011-02-04 | $178.49M 10-K · filed 2011-02-04 | |
| 2008-09-30 | $77.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | $167.03M 10-Q · filed 2009-10-21 | ||
| 2008-06-30 | $89.53M 10-Q · filed 2009-07-17 | |||
| 2007-12-31 | $489.18M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |